Engineered T-Cell Company Raises $56m And Lands New CEO
This article was originally published in Scrip
Executive Summary
The UK's next-generation engineered T-cell immunotherapy company Autolus Ltd. has raised £40m ($56m) in a Series B financing that includes the first investment by the new UK investment firm, Perceptive Bioscience Investments Ltd., and funding from Woodford Investment Management LLP. The round brings Autolus's total funding to a respectable £70m in less than two years.
You may also be interested in...
Next-Generation CAR-Ts Tackle First-Generation Safety, Solid Tumor Challenges
New strategies to overcome safety, solid tumor and other challenges associated with CAR-T therapies – and some early clinical data for patients treated with Poseida's, Celyad's and Autolus' novel products – were featured at the American Association for Cancer Research (AACR) meeting.
Finance Watch: Genocea, Mateon Shift Strategies, Cut Jobs To Preserve Cash
Genocea shifts to preclinical neoantigen-based cancer vaccines rather than advance a Phase III-ready herpes program on its own and Mateon gives up on its lead drug as placebo outperforms. Also, Juno tops recent public company financings and new VC funds back early-stage firms.
A Supercharged Charitable Investment Fund To Nurture UK's Biotech Ecosystem
The UK’s largest medical charities, the Wellcome Trust and Cancer Research UK, have backed the formation of a bulked-up £1bn long-term investment fund from the bringing together of Syncona, the CRT Pioneer Fund and BACIT, with the aim of building a self-sustaining UK biotech ecosystem.